Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237270 | 0.86 | CA2 (0.39) | GABRA1GABRB2CA2KIF11CREBBP | |
| SCHEMBL19725752 | 0.80 | GABRA1 (0.41) | GABRA1GABRB2BRD4CREBBPALDH1A1 | |
| SCHEMBL21237269 | 0.77 | GABRA1 (0.42) | GABRA1GABRB2CA2KIF11NLRP3 | |
| SCHEMBL19660438 | 0.77 | CYP2A6 (0.44) | GABRA1GABRB2NLRP3BRD4CREBBP | |
| SCHEMBL21237180 | 0.76 | KDM5A (0.36) | CA2ALDH1A1 | |
| SCHEMBL20012925 | 0.75 | NOS2 (0.41) | GABRA1GABRB2BRD4CREBBPALDH1A1 | |
| SCHEMBL21237195 | 0.75 | CYP1A2 (0.38) | GABRA1GABRB2CA2KIF11ALDH1A1 | |
| SCHEMBL21237177 | 0.75 | CA2 (0.34) | GABRA1GABRB2CA2KIF11CREBBP | |
| SCHEMBL21237268 | 0.72 | CA2 (0.35) | GABRA1GABRB2CA2KIF11ALDH1A1 | |
| SCHEMBL2605773 | 0.68 | CYP2E1 (0.39) | CA2KIF11ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | GABRA1 2040/4885GABRB2 2380/4885CA2 3042/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | GABRA1 2040/4885GABRB2 2380/4885CA2 3042/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | GABRA1 2040/4885GABRB2 2380/4885CA2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.